|Table of Contents|

The whole process management of pancreatic cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4555-4561
Research Field:
Publishing date:

Info

Title:
The whole process management of pancreatic cancer patients
Author(s):
YAN Mingyue1; ZHAN Xianbao2; PENG Xiaobo2
1.School of Basic Medical Sciences，Naval Medical University，Shanghai 200433，China;2.Department of Oncology，the First Affiliated Hospital of Naval Military Medical University，Shanghai 200433，China.
Keywords:
pancreatic tumor; ultidisciplinary joint clinic; whole-process management
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2024.23.020
Abstract:
Pancreatic cancer is characterized by its insidious onset,difficulty in early diagnosis,and high degree of malignancy.Treatment methods from a single discipline or at a single point in time are insufficient to meet the requirements for treating pancreatic cancer.Comprehensive management of pancreatic cancer patients is achieved through monitoring risk factors and high-risk groups and using biological markers for early diagnosis.After onset,diagnosis and staging are performed using multidisciplinary approaches to select the most suitable treatment method for the patient.During treatment,a multidisciplinary approach is used to achieve better therapeutic effects and improve the patient's quality of life and follow-up assessments are conducted post-treatment to promptly understand recurrence,metastasis,and progression.In other words,a comprehensive management model is adopted,through collaboration among multidisciplinary teams,to scientifically develop personalized treatment plans that improve the patient's quality of life.This article introduces the concept of comprehensive management of pancreatic cancer patients based on the diagnostic and therapeutic methods of various disciplines,and reviews the research progress in the comprehensive management of pancreatic cancer in recent years,with the aim of providing reference and insights for clinical practitioners.

References:

［1］BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］国家卫生健康委办公厅.胰腺癌诊疗指南(2022年版)［J］.临床肝胆病杂志,2022,38(05):1006-1030. Office of the National Health Commission.Pancreatic cancer diagnosis and treatment guidelines(2022 edition)［J］.Journal of Clinical Hepatobiliary Diseases,2022,38(05):1006-1030.
［3］ZOU SY， SHEN BY.Pay attention to whole cycle management of pancreatic cancer［J］.Chinese Journal of Surgery,2023,61（7）:550-555.
［4］尚卿，王小磊.1990-2019年中国和美国胰腺癌发病率长期趋势分析［J］.现代肿瘤医学，2024，32（13）:2433-2438. SHANG Q,WANG XL.Analysis of long-term trends in incidence of pancreatic cancer in China and the United States from 1990 to 2019［J］.Modern Oncology,2024,32(13):2433-2438.
［5］海静，罗和生.不同性别胰腺癌患者临床病理特点探究［J］.胃肠病学和肝病学杂志，2021，30（06）:702-706. HAI J,LUO HS.Investigation on the clinicopathological characteristics of pancreatic cancer patients of different genders［J］.Journal of Gastroenterology and Hepatology,2021,30(06):702-706.
［6］NAM DJ， OH CM， HA E，et al.The association of pancreatic cancer incidence with smoking status and smoking amount in Korean men［J］.Epidemiol Health,2022,44:e2022040.
［7］GO VL， GUKOVSKAYA A， PANDOL SJ.Alcohol and pancreatic cancer［J］.Alcohol,2005,35（3）:205-211.
［8］GARCIA DI， HURST KE， BRADSHAW A，et al.High-fat diet drives an aggressive pancreatic cancer phenotype［J］.J Surg Res,2021,264:163-172.
［9］吕珂，颜晓一.超声诊治胰腺疾病进展［J］.中国医学影像技术，2024，40（04）:481-484. LYU K,YAN XY.Progress in the diagnosis and treatment of pancreatic diseases by ultrasound［J］.Chinese Journal of Medical Imaging Technology,2024,40(04):481-484.
［10］MIURA F， TAKADA T， AMANO H，et al.Diagnosis of pancreatic cancer［J］.HPB,2006,8（5）:337-342.
［11］WANG S， ZHANG Y， XU Y，et al.Progress in the application of dual-energy CT in pancreatic diseases［J］.Eur J Radiol,2023,168:111090.
［12］JHA P， YEH BM， ZAGORIA R，et al.The role of MR imaging in pancreatic cancer［J］.Magn Reson Imaging Clin N Am,2018,26（3）:363-373.
［13］贾青青，张俊文.超声内镜技术在胆胰疾病诊治中的应用研究进展［J］.胃肠病学和肝病学杂志，2024，33（04）:459-462. JIA QQ,ZHANG JW.Research progress on the application of endoscopic ultrasound technology in the diagnosis and treatment of biliary and pancreatic diseases［J］.Journal of Gastroenterology and Hepatology,2024,33(04):459-462.
［14］GOYAL H， SHERAZI SAA， GUPTA S，et al.Application of artificial intelligence in diagnosis of pancreatic malignancies by endoscopic ultrasound:a systemic review［J］.Therap Adv Gastroenterol,2022,15:17562848221093873.
［15］华俊，李岚，杨媛媛，等.Ga-FAPI-04 PET/CT对胰腺癌的诊断价值及对肿瘤分期的影响［J］.中国肿瘤临床，2024，51（03）:118-123. HUA J,LI L,YANG YY,et al.Diagnostic value of Ga-FAPI-04 PET/CT for pancreatic cancer and its impact on tumor staging［J］.Chinese Journal of Clinical Oncology,2024,51(03):118-123.
［16］SCARA S，BOTTONI P，SCATENA R.CA 19-9:Biochemical and clinical aspects［J］.Advances in Cancer Biomarkers,2015,867:247-260.
［17］侯亚，骆焕.血清CEA，CA125，AFP与慢性乙型肝炎病情的相关性［J］.哈尔滨医药，2024，44（03）:26-28. HOU Y,LUO H.Correlation between serum CEA,CA125,AFP and the condition of chronic hepatitis B［J］.Harbin Medical Journal,2024,44(03):26-28.
［18］郭鹏伟，赵红梅，王毅，等.晚期结直肠癌患者靶向治疗前后血清CEA，CA125，CA199变化及与疗效的关系［J］.河北医药，2024，46（12）:1849-1852. GUO PW,ZHAO HM,WANG Y,et al.Changes in serum CEA,CA125,CA199 levels before and after targeted therapy in patients with advanced colorectal cancer and their relationship with therapeutic efficacy［J］.Hebei Medicine,2024,46(12):1849-1852.
［19］李灿.血清CEA，CA199，PGⅠ，PGⅡ在Hp阳性早期胃癌诊断中应用价值［J］.罕少疾病杂志，2024，31（06）:81-83. LI C.The application value of serum CEA,CA199,PGⅠ,PGⅡ in the diagnosis of early gastric cancer with positive Hp［J］.Journal of Rare and Less Common Diseases,2024,31(06):81-83.
［20］AHMADIPOUR M， BHATTACHARYA A， SARAFBIDABAD M，et al.CA19-9 and CEA biosensors in pancreatic cancer［J］.Clin Chim Acta,2024,554:117788.
［21］SIMON KS.EUS-FNA和EUS-FNB在疑似胰腺癌活检中的效率Meta分析［D］.郑州：郑州大学，2022. SIMON KS.Efficiency Meta-analysis of EUS-FNA and EUS-FNB in suspected pancreatic cancer biopsy［D］.Zhengzhou:Zhengzhou University,2022.
［22］FENG Q， LIAO W， XIN Z，et al.Laparoscopic pancreaticoduodenectomy versus conventional open approach for patients with pancreatic duct adenocarcinoma:An up-to-date systematic review and meta-analysis［J］.Front Oncol,2021,11:749140.
［23］张文杰，谭云波.机器人与腹腔镜在胰腺癌微创治疗中的应用进展［J］.医学综述，2018，24（19）:3904-3908,3913. ZHANG WJ,TAN YB.The application progress of robots and laparoscopy in minimally invasive treatment of pancreatic cancer［J］.Medical Review,2018,24(19):3904-3908,3913.
［24］MIZRAHI JD，SURANA R，VALLE JW，et al.Pancreatic cancer［J］.Lancet，2020，395（10242）:2008-2020.
［25］WOOD LD,CANTO MI，JAFFEE EM，et al.Pancreatic cancer:pathogenesis， screening， diagnosis， and treatment［J］.Gastroenterology，2022，163（2）:386-402.
［26］LIERMANN J，NAUMANN P，WEYKAMP F，et al.Effectiveness of carbon ion radiation in locally advanced pancreatic cancer［J］.Front Oncol，2021，11:708884.
［27］BAILEY P，CHANG D，NONES K,et al.Genomic analyses identify molecular subtypes of pancreatic cancer［J］.Nature,2016,531(7592):47-52.
［28］HONG DS，FAKIH MG，STRICKLER JH，et al.KRASG12C inhibition with sotorasib in advanced solid tumors［J］.N Engl J Med，2020，383:1207-1217.
［29］王道超，吴剑慧，张晓萌，等.靶向KRAS突变型胰腺癌药物治疗研究进展［J］.北京医学，2022，44（06）:521-525. WANG DC,WU JH,ZHANG XM,et al.Research progress in drug treatment targeting KRAS mutant pancreatic cancer［J］.Beijing Medical,2022,44(06):521-525.
［30］MAJIDPOOR J，MORTEZAEE K.The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives［J］.Clin Immunol，2021，226:108707.
［31］田静，张之勇，白天凯，等.嵌合抗原受体T细胞免疫疗法治疗胰腺癌的研究进展［J］.实用医学杂志，2022，38（04）:516-521. TIAN J,ZHANG ZY,BAI TK,et al.Research progress on chimeric antigen receptor T-cell immunotherapy for the treatment of pancreatic cancer［J］.Journal of Practical Medicine,2022,38(04):516-521.
［32］谢广伦，郭大鹏，李志刚，等.CT引导下腹腔神经丛毁损治疗癌性上腹痛的效果［J］.郑州大学学报（医学版），2020，55（02）:266-270. XIE GL,GUO DP,LI ZG,et al.Effect of celiac plexus neurolysis under CT guidance in the treatment of cancerous upper abdominal pain［J］.Journal of Zhengzhou University(Medical Edition),2020,55(02):266-270.
［33］高灵花，陈颖，沈金花.早期肠内营养联合肠黏膜保护对胰腺癌根治术后患者营养不良，免疫功能和胃肠功能的影响［J］.海南医学，2023，34（18）:2595-2598. GAO LH,CHEN Y,SHEN JH.The effect of early enteral nutrition combined with intestinal mucosal protection on malnutrition,immune function,and gastrointestinal function in patients after radical resection of pancreatic cancer［J］.Hainan Medical Journal,2023,34(18):2595-2598.
［34］张卫国，王晶，范俊利，等.早期肠内营养支持在食管癌患者围手术期中的应用研究［J］.河南科技大学学报（医学版），2018，36（01）:29-33. ZHANG WG,WANG J,FAN JL,et al.Research on the application of early enteral nutrition support in perioperative period of esophageal cancer patients［J］.Journal of Henan University of Science and Technology(MedicalScience),2018,36(01):29-33.
［35］刘鲁明.中西医结合治疗胰腺癌的机遇与挑战［J］.中国中西医结合杂志，2019，39（01）:18-20. LIU LM.Opportunities and challenges in the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine［J］.Chinese Journal of Integrated Traditional and Western Medicine,2019,39(01):18-20.
［36］彭杰超.新辅助/转化治疗在交界可切除（BR）/局部进展晚期（LA）胰腺癌中的价值研究［D］.青岛：青岛大学，2023. PENG JC.Study on the value of neoadjuvant/conversion therapy in borderline resectable(BR)/locally advanced(LA) pancreatic cancer［D］.Qingdao:Qingdao University,2023.
［37］何晓文，张蕾，卢帅伟，等.胰腺癌根治术后应用吉西他滨联合白蛋白紫杉醇辅助化疗的临床观察［J］.河南医学高等专科学校学报，2024，36（01）:23-27. HE XW,ZHANG L,LU SW,et al.Clinical observation of adjuvant chemotherapy with gemcitabine combined with albumin-bound paclitaxel after radical resection of pancreatic cancer［J］.Journal of Henan Medical College,2024,36(01):23-27.
［38］彭峰辉.胰腺癌根治术后吉西他滨单药或白蛋白结合型紫杉醇联合吉西他滨辅助化疗的临床研究［D］.长春：吉林大学，2021. PENG FH.Clinical study on adjuvant chemotherapy with gemcitabine monotherapy or albumin-bound paclitaxel combined with gemcitabine after radical resection of pancreatic cancer［D］.Changchun:Jilin University,2021.
［39］施锦波.接受术后化疗的早期胰腺导管腺癌患者预后分析［D］.杭州：浙江大学，2021. SHI JB.Prognostic analysis of early pancreatic ductal adenocarcinoma patients undergoing postoperative chemotherapy［D］.Hangzhou:Zhejiang University,2021.
［40］朱绪臻，谈帅.术后辅助化疗与同步放化疗治疗胰腺癌的临床效果探讨［J］.中国现代药物应用，2024，18（11）:111-114. ZHU XZ,TAN S.Discussion on the clinical effects of postoperative adjuvant chemotherapy and concurrent chemoradiotherapy in the treatment of pancreatic cancer［J］.Chinese Journal of Modern Drug Application,2024,18(11):111-114.
［41］虞先濬，刘亮，徐华祥，等.胰腺癌综合诊治指南（2018版）［J］.临床肝胆病杂志，2018，34（10）:2109-2120. YU XJ,LIU L,XU HX,et al.Pancreatic cancer comprehensive diagnosis and treatment guidelines(2018 edition)［J］.Journal of Clinical Hepatobiliary Diseases,2018,34(10):2109-2120.

Memo

Memo:
National Natural Science Foundation of China（No.82072707）;国家自然科学基金项目（编号：82072707）；海军军医大学第一附属医院基础医学研究专项项目（编号：2023PY29）
Last Update: 2024-11-01